The Ohio State University Dermatology Biorepository

Hidradenitis Suppurativa Clinical Trial

Official title:

The Ohio State University Dermatology Biorepository

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03146676
• Other study ID #: 2010H0331
• Status: Recruiting
• Start date: April 19, 2017
• Est. completion date: December 31, 2030

Study information

• Verified date: April 2024
• Source: Ohio State University
• Contact: Erin Frey
• Phone: 614-366-2025
• Email: erin.frey[@]osumc.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.

Description:

A variety of molecular techniques can be used to investigate diseases by analyzing protein, DNA, and RNA. Flow cytometry, Polymerase chain reaction (PCR), histology and immunohistochemistry are assays which can identify specific cell populations and provide valuable information regarding the pathologic characteristics of those populations. Flow cytometry analyzes the surface markers of cells. Histology and immunohistochemistry further characterize surface and cellular molecules and aid in the diagnosis of certain skin diseases. Gene expression profiling allows investigators to examine the genes detectable to determine the function of the cells involved, and PCR techniques are useful for the diagnosis of certain conditions and for DNA analysis. By procuring blood, skin tissue, and swab samples from patients with and without neoplastic and inflammatory skin disorders at the time of their appointments, the hypothesize that future translational research can be conducted on such specimens using the aforementioned techniques to further understand disease mechanisms in cutaneous disorders, and to potentially discover defective function and genetic mutations within cells from patients with neoplastic and inflammatory skin disorders. By establishing a tissue bank, we aim to lay the foundation for future work that will improve our understanding of the biology and natural history of neoplastic and inflammatory cutaneous diseases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 175
• Est. completion date: December 31, 2030
• Est. primary completion date: December 31, 2030
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Seen by an Ohio State University (OSU) Dermatology provider on the main University Hospital campus, including the James Cancer Hospital, OSU Dermatology East, OSU Dermatology at the Ohio State Eye and Ear Institute, Martha Morehouse Medical Pavilion, and OSU Dermatology at Upper Arlington after the date of approval of this protocol
• Ability to provide informed consent, or parent or legal guardian capable of providing consent for child or mentally handicapped individuals
• Willingness to participate in a research study.

Exclusion Criteria:

• Inability to provide informed consent

Related Conditions & MeSH terms

• Hidradenitis
• Hidradenitis Suppurativa

Locations

Country	Name	City	State
United States	OSU Dermatology West	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Source of clinical specimens for the future study of neoplastic and inflammatory skin disorders		5 years